scorecardresearchDivis Laboratories Share Price 3,610.45

Divis Laboratories

BSE: 532488 | NSE: DIVISLAB | ISIN: INE361B01024 | SECTOR: Biotechnology & Drugs

3,610.45 0.00 (0%)

05 Jul 2022, 09:59 (IST)
  • Open

    3,650.00
  • High

    3,678.45
  • Low

    3,603.35
  • Prev Close

    3,638.40
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    -
  • Volume

    5.23K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    3,610.35
  • Ask

    -
  • 3,603.35
  • Intraday
  • 3,678.45
  • 3,365.10
  • 52 Wk H/L
  • 5,425.00
  • 3,274.60
  • DPR
  • 4,002.20

Key Metrics

- Mkt. Cap.

V

Volatility %

Market Sentiment

  • Neutral
B

Beta -

Genie Says

Influencer Count

42

Financials

  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)
52 Week
High
52 Week
Low
Market Cap.
(Cr)

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    Simple Moving Averages

    DaysBSENSE

    Divis Laboratories is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    Company Description

    • Large Cap
    • Automobiles
    • BSE

      532488
    • NSE

      DIVISLAB
    • ISIN

      INE361B01024

    Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

    Company Officers

    • Kiran Divi

      Chief Executive Officer, Whole-time Director
    • L. Kishore Babu

      Chief Financial Officer
    • M. Satish Choudhury

      Chief Compliance Officer, Company Secretary
    • Murali Divi

      Managing Director, Executive Director
    • Madhusudana Divi

      Whole-Time Director (Projects)
    • Nilima Divi

      Whole-Time Director
    • N. Ramana

      Executive Director